ALKSMore pills, fewer headaches
ALK is deepening its strategic tablet supply partnership with Catalent, and this one is all about making sure the supply chain doesn’t get cute. The deal gives ALK long-term expanded access to Catalent’s fast-dissolving Zydis tablet formulation technology.
Capacity: the unsexy thing that matters
The headline nugget here is manufacturing muscle. Catalent will prioritize a capacity increase of roughly 40%, taking annual output to about 1.1 billion tablets from the early 2030s. That’s not flashy, but it’s the kind of operational detail that can make a company look a lot more reliable when demand rises.
Why investors should care
For a pharma company, supply robustness is basically the corporate version of having enough batteries before a hurricane. If ALK can count on steadier production, it can support product availability and avoid the awkward “great demand, not enough tablets” problem.
Big picture: this looks less like a headline-grabbing moonshot and more like ALK quietly buying itself some operational breathing room.